12th Annual Indiana CTSI Disease and Therapeutic Response Modeling Symposium
2/23/23- Day 2
*Not all videos of the conference all available
Video 1 of 2
Opening Remarks
Sara K. Quinney, PharmD, PhD; Indiana University School of Medicine
Alzheimer's disease (AD) dementia disease progression model for mild cognitive impairment, and mild and moderate dementia due to AD, using the integrated AD Rating Scale (iADRS): meta-analyses across six trials
Ivelina Gueorguieva, PhD; Eli Lilly and Company
Donanemab Exposure Efficacy Relationship in Patients with Early Symptomatic Alzheimer's Disease
Steve Ernest, PhD; Eli Lilly and Company
Ivelina Gueorguieva, PhD; Eli Lilly and Company
Deep multi-omic network fusion revaleas altered synaptic network in Alzheimer's disease
Jingwen Yan, PhD; IUPUI Department of BioHealth Informatics
Pharmacokinetics of SHIP1 inhibitors in a mouse model of Alzheimer's disease: Comparison of in silico and in vivo pharmacokinetics
Murugesh Kandasamy, PhD; IU Disease and Therapeutic Response Modeling Program
Translational insight to answer the question: Vancomycin, should we get precise?
Marc H. Scheetz, PharmD, MSc, FCCP, FCP; Pharmacometrics Center of Excellence Midwestern University
Review of population pharmacokinetic studies of opioids in maternal & pediatric populations
Mohammad Yaseen Abbasi, PharmD; IU Disease & Therapeutic Response Modeling Program
- Tags
-
